ArticleCalcified tissue international2026
Gut Microbiota-Derived TMAO Drives MC3T3-E1 Senescence and Osteogenic Dysfunction via cGAS-STING-NF-κB Signaling: Implications for Age-Related Bone Loss.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Age-related osteoporosis is closely associated with osteoblast dysfunction, in which cellular senescence plays a key role. Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, is implicated in aging and metabolic diseases and has been linked to bone metabolism. However, whether TMAO impairs bone formation by regulating osteoblast senescence remains unclear. This study investigated the effects of TMAO on osteoblast senescence and osteogenic function, focusing on the cGAS-STING-NF-κB signaling axis. MC3T3-E1 cells were treated with TMAO to evaluate proliferation, cell cycle progression, senescence, and osteogenic differentiation. Cytosolic DNA release and activation of the cGAS-STING-NF-κB axis were assessed. In vivo, a chronic TMAO exposure model was established, combined with AAV9-mediated STING knockdown, and bone microarchitecture was analyzed by micro-CT. TMAO significantly inhibited proliferation and induced G0/G1 arrest in MC3T3-E1 cells without apparent cytotoxicity. It increased SA-β-gal-positive cells and upregulated senescence-associated markers, indicating a senescent phenotype. Functionally, TMAO suppressed osteogenic differentiation and mineralization and downregulated osteogenic proteins. Mechanistically, TMAO promoted abnormal release of mitochondrial DNA into the cytosol, activated the cGAS-STING pathway, and enhanced NF-κB signaling. STING overexpression exacerbated, whereas STING knockdown alleviated, TMAO-induced senescence and osteogenic impairment. NF-κB inhibition partially reversed these effects. In vivo, TMAO exposure impaired trabecular and cortical bone microarchitecture, which was partially improved by STING knockdown. TMAO induces osteoblast senescence and impairs osteogenic function, potentially via mtDNA-mediated activation of the cGAS-STING-NF-κB axis. These findings provide insight into age-related bone loss and suggest potential therapeutic targets.
Indexed as
Identifiers
42366244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.